TOI Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of 11.82%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Encompass Health Corp.'s return on equity of 24.34%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 81.06%. On the other hand Encompass Health Corp. has an analysts' consensus of $140.33 which suggests that it could grow by 41.22%. Given that The Oncology Institute, Inc. has higher upside potential than Encompass Health Corp., analysts believe The Oncology Institute, Inc. is more attractive than Encompass Health Corp..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.756, suggesting its less volatile than the S&P 500 by 24.396%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health Corp. offers a yield of 0.73% to investors and pays a quarterly dividend of $0.19 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Encompass Health Corp. pays out 14.35% of its earnings as a dividend. Encompass Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. The Oncology Institute, Inc.'s net income of -$13.8M is lower than Encompass Health Corp.'s net income of $174.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Encompass Health Corp.'s PE ratio is 18.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.67x versus 1.75x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pediatrix Medical Group, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of 14.55%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Pediatrix Medical Group, Inc.'s return on equity of 20.22%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 81.06%. On the other hand Pediatrix Medical Group, Inc. has an analysts' consensus of $22.67 which suggests that it could grow by 2.06%. Given that The Oncology Institute, Inc. has higher upside potential than Pediatrix Medical Group, Inc., analysts believe The Oncology Institute, Inc. is more attractive than Pediatrix Medical Group, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison Pediatrix Medical Group, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.542%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pediatrix Medical Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Pediatrix Medical Group, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are smaller than Pediatrix Medical Group, Inc. quarterly revenues of $492.9M. The Oncology Institute, Inc.'s net income of -$13.8M is lower than Pediatrix Medical Group, Inc.'s net income of $71.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Pediatrix Medical Group, Inc.'s PE ratio is 11.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.67x versus 0.99x for Pediatrix Medical Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of -22162.75%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat Kindly MD, Inc.'s return on equity of -91.57%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 81.06%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 211.41%. Given that Kindly MD, Inc. has higher upside potential than The Oncology Institute, Inc., analysts believe Kindly MD, Inc. is more attractive than The Oncology Institute, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. The Oncology Institute, Inc.'s net income of -$13.8M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.67x versus 11.25x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

U.S. Physical Therapy, Inc. has a net margin of -10.08% compared to The Oncology Institute, Inc.'s net margin of 9.98%. The Oncology Institute, Inc.'s return on equity of -9486.64% beat U.S. Physical Therapy, Inc.'s return on equity of 8.6%.

The Oncology Institute, Inc. has a consensus price target of $6.50, signalling upside risk potential of 81.06%. On the other hand U.S. Physical Therapy, Inc. has an analysts' consensus of $105.33 which suggests that it could grow by 20.42%. Given that The Oncology Institute, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe The Oncology Institute, Inc. is more attractive than U.S. Physical Therapy, Inc..

The Oncology Institute, Inc. has a beta of 0.151, which suggesting that the stock is 84.902% less volatile than S&P 500. In comparison U.S. Physical Therapy, Inc. has a beta of 1.290, suggesting its more volatile than the S&P 500 by 28.981%.

The Oncology Institute, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. U.S. Physical Therapy, Inc. offers a yield of 2.06% to investors and pays a quarterly dividend of $0.45 per share. The Oncology Institute, Inc. pays -- of its earnings as a dividend. U.S. Physical Therapy, Inc. pays out 95.62% of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

The Oncology Institute, Inc. quarterly revenues are $136.6M, which are smaller than U.S. Physical Therapy, Inc. quarterly revenues of $197.1M. The Oncology Institute, Inc.'s net income of -$13.8M is lower than U.S. Physical Therapy, Inc.'s net income of $19.7M. Notably, The Oncology Institute, Inc.'s price-to-earnings ratio is -- while U.S. Physical Therapy, Inc.'s PE ratio is 36.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for The Oncology Institute, Inc. is 0.67x versus 1.75x for U.S. Physical Therapy, Inc.. Usually stocks with elevated PS ratios are considered overvalued.